查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1824315

2025年治疗诊断学全球市场报告

Theranostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年，治疗诊断学市场将快速成长，到2029年将达到1,849.4亿美元，复合年增长率为10.7%。预测期内的增长可归因于对精准医疗日益增长的关注、肿瘤学、人口老龄化和慢性病领域之外的应用扩展、生物标誌物发现的进步以及政府的支持和资金筹措。预测期内的主要趋势包括监管支持、伴随诊断的兴起、对癌症的关注度增加、意识提升以及技术融合。

未来五年10.7%的成长率预测比我们先前的预测略有下降0.2%。这一下降主要源自于美国与其他国家之间关税的影响。征收关税可能会扰乱美国医疗供应链，增加从比利时和澳洲进口的镏-177前列腺特异性膜抗原放射性配体的成本，从而可能危及靶向癌症治疗，并增加核医学领域的费用。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，其影响也将更加广泛。

预计治疗诊断学市场的成长将受到癌症盛行率上升的推动。癌症的特征是细胞不受控制地增殖，影响各个器官，是全球发病率和死亡率的重要原因。治疗诊断学整合了治疗和诊断，在癌症和慢性病的管理方面具有巨大潜力。透过结合诊断和治疗能力，这种方法可以促进个人化、标靶治疗，并推动医疗保健领域的创新。因此，癌症患者数量的增加将有助于治疗诊断学市场的扩张。例如，截至 2022 年 1 月，美国国家癌症美国(NCI) 报告称，美国约有 5.4% 的人口（即 1,810 万人）是癌症倖存者。此外，2022 年有 623,405 人患有转移性乳腺癌、前列腺癌、肺癌、大肠直肠癌、乳癌癌和转移性黑色素瘤，预计到 2025 年这一数字将增加到 693,452。因此，癌症盛行率的上升是治疗诊断学市场的主要驱动力。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 治疗诊断学 Global：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球治疗诊断学市场：成长率分析
  • 全球治疗诊断学市场表现：规模与成长，2019-2024
  • 全球治疗诊断学市场预测：规模与成长，2024-2029 年，2034 年
  • 全球治疗诊断学：总目标市场（TAM）

第六章 市场细分

  • 全球治疗诊断学市场：依疾病类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 神经系统疾病
  • 心血管疾病
  • 免疫疾病
  • 肿瘤疾病
  • 其他疾病
  • 全球治疗诊断学市场：依技术、绩效与预测，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素链锁反应
  • 免疫组织化学
  • 原位杂交
  • 定序
  • 其他技术
  • 全球治疗诊断学市场：按最终用户、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院和诊所
  • 诊断实验室
  • 其他最终用户
  • 全球治疗诊断学市场：依神经系统疾病（类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 癫痫
  • 其他神经系统疾病
  • 全球治疗诊断学市场：依心血管疾病类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 冠状动脉疾病
  • 心臟衰竭
  • 心房颤动
  • 高血压
  • 其他心血管疾病
  • 全球治疗诊断学市场：依免疫疾病类型细分，实质及预测，2019-2024 年、2024-2029 年、2034 年
  • 类风湿性关节炎
  • 全身性红斑性狼疮
  • 发炎性肠道疾病
  • 银屑病
  • 其他免疫疾病
  • 全球治疗诊断学市场：依肿瘤疾病类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 其他肿瘤疾病
  • 全球治疗诊断学市场：依疾病类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 感染疾病
  • 代谢紊乱
  • 遗传性疾病
  • 其他疾病

第七章 区域和国家分析

  • 全球治疗诊断学市场：区域表现及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 全球治疗诊断学市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 治疗诊断学市场：竞争格局
  • 治疗诊断学市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
    • Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Astellas Pharma
  • Helmholtz Centre for Infection Research
  • Radiopharm Theranostics Ltd
  • Alpha-Theranostics
  • UNIVERZITET U NOVOM SADU
  • Cardio-Theranostics LLC
  • Curium
  • SoFi Technologies Inc.
  • Theradiag
  • Cell Theranostics
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc
  • Qiagen NV
  • Foundation Medicine Inc
  • Leica Biosystems Nussloch GmBH

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029 年治疗诊断学市场：提供新机会的国家
  • 2029 年治疗诊断学市场：细分领域带来新机会
  • 2029 年治疗诊断学市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r24554u

Theranostics is a medical discipline that integrates therapeutics and diagnostics into a unified approach. It entails the development and application of diagnostic tests that not only identify diseases or conditions but also furnish information for guiding personalized therapeutic interventions.

Various types of theranostics are categorized by disease type, encompassing neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Neurological disorders comprise a spectrum of conditions affecting the brain, spinal cord, and nerves, leading to diverse symptoms and impairments. Theranostics plays a crucial role in ensuring precise diagnosis, monitoring disease progression, and guiding personalized treatment strategies for these disorders. The technologies employed for theranostics encompass polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others. These technologies find application across different end-users, including hospitals and clinics, diagnostic laboratories, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The theranostics market research report is one of a series of new reports from The Business Research Company that provides theranostics market statistics, including the theranostics industry's global market size, regional shares, competitors with a theranostics market share, detailed theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. This theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The theranostics market size has grown rapidly in recent years. It will grow from $111.1 billion in 2024 to $122.98 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to advancements in molecular imaging, shift to value-based healthcare, integration in oncology.

The theranostics market size is expected to see rapid growth in the next few years. It will grow to $184.94 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rise in precision medicine initiatives, expanding applications beyond oncology, population aging and chronic diseases, advancements in biomarker discovery, government support and funding. Major trends in the forecast period include regulatory support, rise of companion diagnostics, increased focus on cancer theranostics, patient engagement and awareness, technological convergence.

The forecast of 10.7% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for lutetium-177 Prostate-Specific Membrane Antigen theranostic radioligands imported from Belgium and Australia, potentially compromising targeted cancer therapy and raising nuclear medicine department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the theranostics market is expected to be driven by the increasing prevalence of cancer. Cancer, characterized by uncontrolled cell growth affecting various organs, remains a significant source of morbidity and mortality globally. Theranostics, integrating therapeutics and diagnostics, holds substantial promise in cancer and chronic disease management. This approach facilitates personalized and targeted treatments by combining diagnostic and therapeutic capabilities, fostering innovation in the healthcare sector. Consequently, the rise in the number of cancer patients is poised to contribute to the expansion of the theranostics market. For instance, as of January 2022, the National Cancer Institute (NCI) reported that approximately 5.4% of the U.S. population, equivalent to 18.1 million individuals, are cancer survivors. Furthermore, there were 623,405 people living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in 2022, with projections indicating an increase to 693,452 by 2025. Thus, the increasing prevalence of cancer is a key driver for the theranostics market.

The expected growth of the theranostics market is also anticipated to be fueled by the growing investment in research and development. Research and development (R&D) constitute a series of activities conducted by individuals, universities, corporations, and governments to discover new knowledge, create new products or processes, or enhance existing ones. In the realm of theranostics, R&D efforts aim to deliver both imaging and therapeutic agents specifically to diseased tissues, minimizing side effects and maximizing therapeutic efficacy. For instance, in April 2023, the National Cancer Institute (NCI) allocated $437,000 in funds to explore the function of enolase in theranostics, a burgeoning field that synergizes therapy and imaging to molecularly target and eliminate cancer cells while preserving healthy tissue. Thus, the increasing investment in research and development serves as a driving force for the theranostics market.

Major companies in the theranostics market are concentrating on developing advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by integrating diagnostics and therapeutics into a unified treatment approach. Theranostics clinical trials are research studies designed to assess the combined use of diagnostic tests and targeted therapies, tailoring treatment strategies to individual patients. These trials focus on evaluating the effectiveness of specific treatments based on patient-specific biomarkers, thereby advancing personalized medicine. For example, in May 2024, BAMF Health, a cancer treatment center based in the U.S., launched the COMBAT Trial, formally titled "A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617" (NCT05633160). This trial features a rapid activation process facilitated by BAMF Health's BAMF RapAct program, allowing it to launch in just seven weeks. It also emphasizes the use of innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR), with the goal of improving treatment options for patients with limited therapeutic alternatives.

Major companies in the theranostics market are concentrating on the development of innovative products, including molecular targeted radiopharmaceuticals (MTRP), to gain a competitive advantage. Molecular targeted radiopharmaceuticals are radioactive drugs used for diagnosing and treating diseases, particularly cancer. An example is the launch of 177Lu(n.c.a.)-PSMA-Therapy by Applied Molecular Therapeutics, a US-based biopharmaceutical company, in February 2022. This MTRP specifically targets the PSMA (prostate-specific membrane antigen) protein on the surface of prostate cancer cells, delivering a high radiation dose directly to the tumor while minimizing damage to healthy tissue. The radioactive 177Lu emitted by the therapy kills the cancer cells after binding to the PSMA protein.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. This strategic acquisition positions Radiopharm to explore next-generation radiopharmaceuticals' potential for treating prostate cancer, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in developing radio-immuno-theranostic platforms and pharmaceutical products.

Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

North America was the largest region in the global theranostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are ""factory gate"" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases
  • 2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
  • 3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
  • Subsegments:
  • 1) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders
  • 2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases
  • 3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders
  • 4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases
  • 5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases
  • Companies Mentioned: Abbott Laboratories; Agilent Technologies Inc.; AmeriPath Inc; Beckman Coulter Inc.; Thermo Fisher Scientific Inc; Astellas Pharma; Helmholtz Centre for Infection Research; Radiopharm Theranostics Ltd; Alpha- Theranostics; UNIVERZITET U NOVOM SADU; Cardio-Theranostics LLC; Curium; SoFi Technologies Inc.; Theradiag; Cell Theranostics; F. Hoffmann-La Roche AG; GE HealthCare Technologies Inc; Qiagen NV; Foundation Medicine Inc; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Siemens Healthineers; Advanced Accelerator Applications; AstraZeneca plc; Bayer AG; Bio-Rad Laboratories; The Bristol-Myers Squibb Company; Danaher Corporation; MilliporeSigma; Illumina Inc.; Merck KGaA; Roche Diagnostics Corporation; PerkinElmer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Theranostics Market Characteristics

3. Theranostics Market Trends And Strategies

4. Theranostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Theranostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Theranostics Market Growth Rate Analysis
  • 5.4. Global Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Theranostics Total Addressable Market (TAM)

6. Theranostics Market Segmentation

  • 6.1. Global Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Neurological Disorders
  • Cardiovascular Diseases
  • Immunological Disorders
  • Oncology Diseases
  • Other Diseases
  • 6.2. Global Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction
  • Immunohistochemistry
  • In-Situ Hybridization
  • Sequencing
  • Other Technologies
  • 6.3. Global Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Other End Users
  • 6.4. Global Theranostics Market, Sub-Segmentation Of Neurological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Other Neurological Disorders
  • 6.5. Global Theranostics Market, Sub-Segmentation Of Cardiovascular Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coronary Artery Disease
  • Heart Failure
  • Atrial Fibrillation
  • Hypertension
  • Other Cardiovascular Diseases
  • 6.6. Global Theranostics Market, Sub-Segmentation Of Immunological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Inflammatory Bowel Disease
  • Psoriasis
  • Other Immunological Disorders
  • 6.7. Global Theranostics Market, Sub-Segmentation Of Oncology Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Other Oncology Diseases
  • 6.8. Global Theranostics Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infectious Diseases
  • Metabolic Disorders
  • Genetic Disorders
  • Other Diseases

7. Theranostics Market Regional And Country Analysis

  • 7.1. Global Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Theranostics Market

  • 8.1. Asia-Pacific Theranostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Theranostics Market

  • 9.1. China Theranostics Market Overview
  • 9.2. China Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Theranostics Market

  • 10.1. India Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Theranostics Market

  • 11.1. Japan Theranostics Market Overview
  • 11.2. Japan Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Theranostics Market

  • 12.1. Australia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Theranostics Market

  • 13.1. Indonesia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Theranostics Market

  • 14.1. South Korea Theranostics Market Overview
  • 14.2. South Korea Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Theranostics Market

  • 15.1. Western Europe Theranostics Market Overview
  • 15.2. Western Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Theranostics Market

  • 16.1. UK Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Theranostics Market

  • 17.1. Germany Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Theranostics Market

  • 18.1. France Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Theranostics Market

  • 19.1. Italy Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Theranostics Market

  • 20.1. Spain Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Theranostics Market

  • 21.1. Eastern Europe Theranostics Market Overview
  • 21.2. Eastern Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Theranostics Market

  • 22.1. Russia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Theranostics Market

  • 23.1. North America Theranostics Market Overview
  • 23.2. North America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Theranostics Market

  • 24.1. USA Theranostics Market Overview
  • 24.2. USA Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Theranostics Market

  • 25.1. Canada Theranostics Market Overview
  • 25.2. Canada Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Theranostics Market

  • 26.1. South America Theranostics Market Overview
  • 26.2. South America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Theranostics Market

  • 27.1. Brazil Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Theranostics Market

  • 28.1. Middle East Theranostics Market Overview
  • 28.2. Middle East Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Theranostics Market

  • 29.1. Africa Theranostics Market Overview
  • 29.2. Africa Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Theranostics Market Competitive Landscape And Company Profiles

  • 30.1. Theranostics Market Competitive Landscape
  • 30.2. Theranostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

31. Theranostics Market Other Major And Innovative Companies

  • 31.1. Astellas Pharma
  • 31.2. Helmholtz Centre for Infection Research
  • 31.3. Radiopharm Theranostics Ltd
  • 31.4. Alpha- Theranostics
  • 31.5. UNIVERZITET U NOVOM SADU
  • 31.6. Cardio-Theranostics LLC
  • 31.7. Curium
  • 31.8. SoFi Technologies Inc.
  • 31.9. Theradiag
  • 31.10. Cell Theranostics
  • 31.11. F. Hoffmann-La Roche AG
  • 31.12. GE HealthCare Technologies Inc
  • 31.13. Qiagen NV
  • 31.14. Foundation Medicine Inc
  • 31.15. Leica Biosystems Nussloch GmBH

32. Global Theranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Theranostics Market

34. Recent Developments In The Theranostics Market

35. Theranostics Market High Potential Countries, Segments and Strategies

  • 35.1 Theranostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Theranostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Theranostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer